Research on colon cancer discussed by P. Gouveris and co-researchers
2008 JAN 16 -- According to a study from Thessaloniki, Greece, "Purpose Our aim was to investigate whether chemotherapy with 5-FU induces an alteration in the levels of topoisomerase I (topo I) in colorectal neoplastic tissues Methods Twenty-five colorectal cancer patients were included in our study; these had undergone surgical resection of the primary tumor, received post-operatively 5-FU-based adjuvant chemotherapy and then suffered from recurrences. In a standard three-step immunohistochemical procedure, a monoclonal antibody to topo I was applied in both specimens from each patient (one from the primary location and a second one from the recurrence)." "Statistical analysis was subsequently performed. Results Malignant cells from the recurrences displayed a statistical significant increase, concerning the levels of topoisomerase I, by comparison with the primary tumors (P = 0.01). The increase in topo I levels did not demonstrate significant correlations with Duke's stage (Fisher's Exact Test P value = 0.496), differentiation grade (P value = 0.661), localization (P value = 0.072), patient sex (P value = 0.434), nor with relapse free interval (P value = 0.493). There was a statistically significant relationship between the age of patients and increase in topo I levels (P = 0.011). Conclusions Topo I expression may be part of the malignant cells' phenotype in recurrent colorectal carcinomas, suggesting a potential role for Topo I in the acquisition of a metastatic phenotype," wrote P. Gouveris and colleagues. The researchers concluded: "The increase of topo I immunohistochemical status is likely to be attributed to 5-FU and given the fact that high levels of topo I correlate with sensitivity to camptothecin, advanced colorectal cancer patients seem to benefit from topo I targeted anticancer drug therapy." Gouveris and colleagues published their study in the Journal of Cancer Research and Clinical Oncology (Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2007;133(12):1011-1015). For more information, contact T.G. Papathomas, 12 Kerkiras St., Thessaloniki 55133, Greece. Publisher contact information for the Journal of Cancer Research and Clinical Oncology is: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Greece, Thessaloniki, Biotechnology, Cancer Research, Chemotherapy, Clinical Oncology, Colon Cancer, Colon Carcinoma, Colorectal, Drug Therapy, Gastroenterology, Medical Device, Monoclonal Antibody, Oncology. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2008, Immunotherapy Weekly via NewsRx.com.
|
